Cargando…
Pharmacovigilance and assessment of drug safety reports during COVID 19
The speed and volume of clinical research to discover effective drug against novel corona virus has been remarkable. To address the unmet medical need, the regulations are made flexible and convenient without any relaxation in drug safety reporting. The pharmacovigilance activities, especially adver...
Autor principal: | Desai, Mira K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7513786/ https://www.ncbi.nlm.nih.gov/pubmed/33033703 http://dx.doi.org/10.4103/picr.PICR_171_20 |
Ejemplares similares
-
Monitoring the safety of drugs and COVID-19 vaccines by the French Pharmacovigilance Centers during the pandemic: A win-win bet with Health Authorities!
por: Jonville-Bera, Annie Pierre, et al.
Publicado: (2023) -
Drug safety alerts of pharmacovigilance programme of India: A scope for targeted spontaneous reporting in India
por: Thota, Prasad, et al.
Publicado: (2018) -
Pharmacovigilance follow-up of patients in the context of the COVID-19 pandemic
por: Grandvuillemin, Aurélie, et al.
Publicado: (2023) -
Global research output in ‘pharmacovigilance’ during 2010–2020
por: Tyagi, Sunil
Publicado: (2022) -
French pharmacovigilance survey of casirivimab - imdevimab monoclonal antibodies in coronavirus disease (COVID-19)
por: de Canecaude, Claire, et al.
Publicado: (2023)